IRBs in 2026: The Biggest Changes Aren't in the Regulations

“What changed this year?” – It’s one of the first questions IRB professionals ask each January. Did the Common Rule change? Did the FDA issue new regulations? Is there another compliance requirement we need to prepare for?

The answer may surprise you.

Not much has changed in the regulations themselves.

Yet, for many IRBs, 2026 may still feel like one of the most transformative years in recent memory. Why? – Because while the regulations have remained relatively stable, the environment in which they’re applied continues to evolve at an unprecedented pace. Research is becoming more complex. Technology is advancing faster than policy. Institutions are expected to demonstrate increasingly mature compliance programs. And regulators continue to provide guidance that raises the bar for operational excellence without rewriting the rulebook.

In other words, the biggest changes aren’t found in the Code of Federal Regulations—they’re found in how IRBs are expected to operationalize those regulations.

Here’s what matters most.

1. Guidance Is Becoming Just as Important as Regulation

Many compliance professionals focus on regulatory changes while overlooking agency guidance. In practice, however, guidance documents often signal where regulators are placing their attention.

One of the most significant developments has been the FDA’s final guidance on Institutional Review Board (IRB) Written Procedures. Rather than creating new requirements, the guidance provides detailed recommendations for documenting how an IRB carries out its responsibilities—from protocol review and expedited review to reporting noncompliance and maintaining records.

For many organizations, this is an opportunity to evaluate whether their standard operating procedures reflect current practice—or whether they have evolved informally over time.

Takeaway: If your IRB’s written procedures haven’t been reviewed in the past few years, 2026 is a good time to revisit them.

2. Operational Excellence Is Becoming a Compliance Expectation

Compliance has always required following regulations.

Increasingly, it also requires demonstrating that your processes are effective.

Inspectors and accreditors aren’t just interested in whether an institution has policies—they want to see evidence that those policies are consistently implemented, staff are appropriately trained, and decisions are well documented.

Strong IRB programs are investing in:

• Routine SOP reviews
• Standardized reviewer training
• Internal quality assurance activities
• Documentation consistency
• Continuous process improvement

The shift is subtle but important: compliance is becoming more proactive than reactive.

3. Single IRB Review Is Maturing

Single IRB (sIRB) review is no longer the newest requirement on the block. Most institutions have experience with reliance arrangements, but many continue refining the operational side of these collaborations.

Questions are shifting from “Do we need a single IRB?” to:

• How do we communicate efficiently with relying sites?
• How should local context be documented?
• What responsibilities remain with the relying institution?
• How do we ensure investigators understand the reliance model?

As multisite research continues to expand, successful reliance depends as much on communication and clearly defined roles as it does on regulatory compliance.

4. Risk-Based Oversight Continues to Gain Momentum

One of the most positive trends in human research protections is the continued emphasis on proportional oversight.

Not every protocol presents the same level of risk, and regulators continue encouraging IRBs to focus their expertise where participant protections matter most.

For many organizations, that means making thoughtful use of exempt categories, expedited review procedures, and the revised continuing review requirements introduced under the 2018 Common Rule.

Efficient oversight isn’t about doing less. It’s about directing time and expertise where they have the greatest impact.

Have questions about how exempt or expedited review actually works in practice? Our FAQ page answers the ones we hear most often.

5. Research Is Evolving Faster Than the Regulations

While the regulations themselves have remained relatively stable, the research enterprise certainly hasn’t.

Artificial intelligence, decentralized clinical trials, wearable technologies, digital therapeutics, and increasingly sophisticated data analytics are changing how research is designed and conducted. Although these innovations have not yet prompted major changes to federal human subjects regulations, they are creating new ethical and operational questions for IRBs.

Rather than introducing entirely new regulatory frameworks, agencies continue encouraging IRBs to apply established ethical principles to emerging technologies.

In our next article, we’ll explore one of these developments in depth: the growing role of artificial intelligence in human subjects research and what every IRB should be considering during protocol review.

Looking Ahead

If there’s one lesson from 2026, it’s this:

The future of IRB oversight isn’t being shaped by sweeping regulatory reform. It’s being shaped by evolving expectations.

Organizations that invest in strong governance, current written procedures, well-trained reviewers, and continuous quality improvement will be better prepared—not only for inspections and accreditation, but for the increasingly complex research environment ahead.

The regulations may not have changed dramatically.

The expectations have.

References:

1. U.S. Food and Drug Administration. (2025). Institutional Review Board (IRB) Written Procedures: Guidance for Institutions and IRBs.
2. U.S. Department of Health and Human Services, Office for Human Research Protections. Guidance on 45 CFR Part 46 (Common Rule).
3. U.S. Department of Health and Human Services. 45 CFR Part 46—Protection of Human Subjects.
4. U.S. Food and Drug Administration. 21 CFR Parts 50 and 56.
5. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report.